论文部分内容阅读
目的：旨在对肝癌高发地区与低发地区慢性肝病患者中ＨＣＶ的感染特征进行比较分析。方法：分析南通地区慢性肝炎和肝癌患者中ＨＣＶ和ＨＢＶ的感染状态、ＨＣＶ核心基因的变异，并与台湾及北京地区的文献资料进行比较。结果：南通地区肝病患者中，ＨＣＶ抗体的阳性率为６．３％，低于北京（２０．７％）和台湾地区（１７．２％）；乙肝与丙肝的双重感染率为３．９％，其值与台湾地区（５．７％）相近，但明显低于北京（１５．０％）地区；在ＨＢｓＡｇ（＋）和ＨＢｓＡｇ（－）肝癌组患者中，ＨＣＶ抗体阳性率分别为６．３％和９．６％，也较北京（３６．５％与２６．３％）和台湾（１２．３％与５６．０％）为低；从慢性肝炎患者中克隆的南通株（ＨＣＶＮ１）病毒核心基因序列，其同源性与日本株（ＨＣＶＪ和ＨＣＶＢＫ）非常接近，高于北京株（ＨＣＶＰＲＣＩ）和台湾株（ＨＣＶＴ），表明中国的ＨＣＶ株同属于日本该病毒的主要型别：另从南通地区肝癌患者中克隆的ＨＣＶ株核心蛋白序列的变异也高于同地区慢性肝炎患者中ＨＣＶ株。结论：在肝癌的发展过程中，不同的高发地区ＨＣＶ感染所起的病原学作用有别，但该病毒核心基因的变异，可使病毒持续性感染，这与慢性肝病向肝癌发展具有密切?
Objective: To compare the characteristics of HCV infection in patients with chronic liver disease in areas of high incidence and low incidence of liver cancer. Methods: The infection status of HCV and HBV and the variation of HCV core gene in patients with chronic hepatitis and hepatocellular carcinoma in Nantong area were analyzed and compared with the literatures in Taiwan and Beijing. Results: The positive rate of HCV antibody in Nantong patients was 6.3%, lower than that in Beijing (20.7%) and Taiwan (17.2%). The double infection rate of hepatitis B and C was 3.9% (5.7%) in Taiwan, but significantly lower than that in Beijing (15.0%). The positive rates of HCV antibody in patients with HBsAg (+) and HBsAg (-) HCC were 6, respectively. 3% and 9.6%, respectively, but also lower than those in Beijing (36.5% and 26.3%) and Taiwan (12.3% and 56.0%). The Nantong strain cloned from patients with chronic hepatitis N1) was highly homologous with that of Japanese strain (HCVJ and HCVBK), higher than that of BeijingPCRPRCI and TaiwanT strain (HCVT) The main type of the virus belonging to Japan: the other from the Nantong region of patients with HCV cloned HCV core protein sequence variation is also higher than in the same region of chronic hepatitis patients H V strain. Conclusion: In the development of HCC, the etiological effects of HCV infection in different high incidence areas are different, but the variation of the core gene of the virus can make the virus persistent infection, which is closely related to the development of HCC.